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Overexpression of cyclooxygenase-2 (Cox-2) is thought to
exert antiapoptotic effects in cancer. Here we show that
the tumor suppressor p53 upregulated Cox-2 in esopha-
geal and colon cancer cell lines by inducing the binding of
nuclear factor-kappaB (NF-kappaB) to its response
element in the COX-2 promoter. Inhibition of NF-kappaB
prevented p53 induction of Cox-2 expression. Cooperation
between p53 and NF-kappaB was required for activation
of COX-2 promoter in response to daunomycin, a DNA-
damaging agent. Pharmacological inhibition of Cox-2
enhanced apoptosis in response to daunomycin, in
particular in cells containing active p53. In esophageal
cancer, there was a correlation between Cox-2 expression
and wild-type TP53 in Barrett’s esophagus (BE) and in
adenocarcinoma, but not in squamous cell carcinoma
(Po0.01). These results suggest that p53 and NF-kappaB
cooperate in upregulating Cox-2 expression, promoting
cell survival in inﬂammatory precursor lesions such as BE.
Oncogene (2006) 25, 5708–5718. doi:10.1038/sj.onc.1209579;
published online 8 May 2006
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Introduction
Cyclooxygenase-2 (Cox-2) catalyses the synthesis of
prostaglandins, prostacyclins and thromboxanes in
inﬂammatory and transformed cells, and in malignant
tissues (Hla et al., 1999; Subbaramaiah and Dannen-
berg, 2003). Expression of Cox-2 is induced by
physiological and stress signals including growth fac-
tors, cytokines, mediators of inﬂammation, tumor
promoters, oxidizing agents and DNA-damaging agents
such as g-irradiation, UV-rays or anticancer drugs (Das
and White, 1997; Rockwell et al., 2004; Wu et al., 2005).
The 50 ﬂanking region of the COX-2 gene contains
several consensus response elements (REs), four of
which play documented roles in Cox-2 expression:
c-AMP response element (CRE), nuclear factor inter-
leukin 6, (NF-IL6), E-box and nuclear factor-kappaB
(NF-kappaB)-binding motifs (Tanabe and Tohnai,
2002; Zhu et al., 2002). Alone or in combination, these
REs control COX-2 expression through multiple signal-
ing cascades, making it an important component in the
response to inﬂammatory and cytotoxic stress.
Enhanced Cox-2 activity and synthesis of prostaglan-
dins (PGs) stimulate proliferation, angiogenesis, inva-
siveness and inhibit apoptosis (reviewed in Tsuji et al.,
2001). Pharmacological Cox-2 inhibitors reduce experi-
mental tumor growth (Harris et al., 2000; Oshima et al.,
2001) and the number of intestinal tumors in patients
with familial adenomatous polyposis (Steinbach et al.,
2000). Overexpression of Cox-2 is common in cancers of
the digestive tract (esophageal squamous cell and
adenocarcinoma, gastric, intestinal and colorectal can-
cers) (Eberhart et al., 1994; Zimmermann et al., 1999;
Buskens et al., 2003; Smith et al., 2005; Birkenkamp-
Demtroder et al., 2005). In esophageal cancers, different
patterns of expression are observed in squamous cell
carcinomas (SCC) and adenocarcinomas (ADC). Cyclo-
oxygenase-2 expression is low in normal, squamous
mucosa, increases in squamous dysplasia but remains
low in most SCC (Shamma et al., 2000; Yu et al., 2003).
In contrast, Cox-2 is often expressed in ADC and is
already detected in Barrett’s mucosa, the precursor
lesion in which squamous cells are replaced by
intestinal-type cells as the consequence of chronic gastric
acid and bile reﬂux (Kaur and Triadaﬁlopoulos, 2002;
Lagorce et al., 2003).
Many signals that activate Cox-2 also induce the
tumor suppressor p53, a transcription factor that
accumulates after post-translation modiﬁcation in re-
sponse to DNA damage, inducing antiproliferative
responses such as cell cycle arrest, DNA repair or
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apoptosis (Sengupta and Harris, 2005). In 1999,
Subbaramaiah et al. (1999) reported that expression of
p53 at high levels in mouse ﬁbroblasts repressed Cox-2,
and proposed that p53 may compete with TATA-
binding proteins for binding to the COX-2 promoter.
More recently, Han et al. (2002) demonstrated an
opposite effect, with namely a physiological, p53-
dependent increase in Cox-2 expression in response to
DNA damage. Dominant-negative RAS or RAF1
mutants suppressed p53-mediated expression of Cox-2,
suggesting an indirect mechanism (Han et al., 2002).
However, how p53 activates this mechanism is un-
known. In this study, we have investigated the role of
NF-kappaB in p53-dependent activation of Cox-2 in
response to DNA damage, and we have analysed the
correlations between TP53 gene mutation status and
Cox-2 expression in esophageal ADC and SCC.
Results
Upregulation of cycloxygenase-2 expression by p53
To demonstrate that p53 induces Cox-2 expression,
increasing amounts of a p53 expression vector (pC53-
SN3) were transfected in the colorectal ADC cell line
HCT116, together with ﬁxed amounts of COX-2-LUC,
a reporter construct containing a 1 kb segment of COX-
2 promoter encompassing major functional REs in the 50
regulatory region of COX-2 (Gilroy et al., 2001). This
fragment contains consensus sites for NF-kappaB, but
no identiﬁed p53-binding site. A sevenfold increase in
luciferase activity was observed with 1 mg of transfected
p53 vector (Figure 1a, left panel). Stable expression of
the HPV16 E6 viral oncoprotein, which destabilizes and
eliminates p53 function, abrogated induction of lucifer-
ase activity upon transfection of p53 (Figure 1a, middle
panel). Transfection of p53 also increased Cox-2
expression in TE-13, a p53-deﬁcient esophageal cancer
cell line (Figure 1a, right panel), as well as in other
cancer cell lines with different p53 functional status
(HCT15, CACO-2, HT29, Saos-2; data not shown).
Next, we generated a stable HCT116 line conditionally
expressing p53 in the presence of tetracyclin (HCT116-
p53ind). Western blot showed that tetracycline-
mediated p53 induction enhanced Cox-2 levels in
HCT116-p53ind and that the increase in Cox-2 protein
paralleled both p53 accumulation and induction of
p21waf1, the product of a typical p53 target gene
(Figure 1b). To further show that p53 could induce
Cox-2 enzymatic activity, we used TE-1, a cell line
derived from a squamous esophageal carcinoma, con-
taining a temperature-sensitive TP53 mutant (Val to
Met at codon 272, V272M). Culture at 321C (in
conditions where V272M preferentially adopts a ‘wild-
type’ conformation) resulted in a strong increase (12-
fold) in the level of COX-2 transcripts (Figure 1c, left
and middle panels), correlated with a fourfold increase
in prostaglandin E2 (PGE2) synthesis (Figure 1c, right
panel). Taken together, these data demonstrate that p53
regulates Cox-2 expression in cell lines derived from
cancers of upper (TE-1, TE-13) or lower (HCT116,
HCT15, CACO-2, HT-29) digestive tract.
Requirement of nuclear factor-kappaB for transactivation
of cycloxygenase-2 by p53
Nuclear factor kappaB is an important transcriptional
regulator of COX-2 in response to inﬂammatory signals
(Jobin et al., 1998; Konturek et al., 2004). To determine
whether NF-kappaB was involved in COX-2 promoter
regulation by p53, HCT116 and TE-13 were transfected
with COX-2-LUC together with increasing amounts of
Figure 1 Upregulation of cyclooxygenase-2 (Cox-2) expression by
p53. (a) p53-dependent induction of a COX-2 reporter construct.
Cells were co-transfected with COX-2-LUC reporter, increasing
amounts of an expression vector for p53 protein (pC53-SN3), and
RSV-bGAL reporter as internal transfection standard. LUC
activity was normalized to bGAL and expressed as fold induction
relative to the activity observed with COX-2-LUC reporter alone.
(b) Increased Cox-2 expression after transfection of p53. Left,
HCT116 cells were transfected either with empty vector (pcDNA3,
CTRL) or with p53 expression vector (pC53-SN3, p53). Right, a
tetracyclin-inducible p53 HCT116 cell line (tet-on) was used (p53-
ind). Cells were treated with tetracyclin (1mg/ml) for 8, 16 and 24 h
and levels of p53, Cox-2 and p21waf1 were detected by Western blot
using b-actin as a loading control. (c) Enhanced COX-2 expression
and enzymatic activity in cells expressing a temperature-sensitive
p53 mutant. TE-1, a cell line expressing the temperature-sensitive
p53 mutant V272M, was used. Left, reverse transcription reverse
transcripition–polymerase chain reaction (RT–PCR) detection of
COX-2 mRNA in cells cultured at 371C (p53 mostly in ‘mutant’,
inactive form) and 321C (p53 mostly in ‘wild-type’, active form).
Middle, real-time (TaqMan) RT–PCR analysis of COX-2 expres-
sion levels. Right, PGE2 production at both temperatures.
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expression vectors for NF-kappaB p65 and/or p50, with
or without pC53-SN3 expression vector (Figure 2a).
Transfection of NF-kappaB subunits alone had only
minor effects on luciferase activity in HCT116 cells,
whereas co-transfection of NF-kappaB and p53 almost
doubled the effect of p53 alone (from 7–8-fold with p53
alone to 14–15-fold with p53 and 1 mg of either p65 or
p50 vectors, or both). In TE-13, co-transfection of p53
and NF-kappaB components had overmultiplicative
effects (from fourfold and twofold with either p53 or
NF-kappaB alone, respectively, to over 25-fold with
both factors). Both p50 and p65 showed cooperative
effects with p53. Next, we used the HCT116-MT9 cells
stably expressing a dominant-negative mutant of I-
kappaB-a (Bentires-Alj et al., 1999b, 2001). Transient
co-transfection of p53 expression vector and COX-2-
p53 cooperates with NF-kappaB in Cox-2 regulation
V Benoit et al
5710
Oncogene
LUC reporter showed that luciferase activity was
reduced by about 50% in HCT116-MT9 as compared
to control cells (Figure 2b), indicating that NF-kappaB
was required to mediate at least part of p53 effects on
COX-2 promoter. To verify that NF-kappaB was
recruited to COX-2 promoter during COX-2 induction
by p53, we performed chromatin immunoprecipitation
(ChIP) assays in HCT116 cells transfected with increas-
ing amounts of p53 expression vector (Figure 2c). In
control cells (transfected with an empty vector), neither
binding of NF-kappaB nor p53 was detected. Upon
transfection of p53, a dose-dependent increase in the
level of p53 bound to the promoter was observed, and
was accompanied by an increase in NF-kappaB binding.
Interestingly, binding of NF-kappaB was detectable
only after transfection of 0.3 and 1 mg of p53 vector,
whereas p53 binding was detectable with only 0.1 mg of
transfected vector. Furthermore, the proportion of input
signal associated with p53 was consistently higher than
with NF-kappaB. These results suggest that p53 binding
helps the binding of NF-kappaB to the COX-2
promoter.
To conﬁrm the role of NF-kappaB in the induction of
Cox-2 by p53, we inhibited NF-kappaB in HCT116-
p53ind cells by using small interfering (si) RNA
(Figure 2d). In cells transfected with a control siRNA,
induction of p53 with tetracyclin resulted in increased
expression of both WAF-1 and COX-2 mRNA. In cells
transfected with p65 siRNA, the increase in COX-2
expression, but not in WAF-1 expression, was inhibited.
Finally, we also used BAY117082, a chemical inhibitor
of NF-kappaB, in TE-1 cells cultured at 32 or 371C.
This inhibitor induced a drastic reduction in levels of
COX-2 mRNA in cells cultured at 321C but had no
effect at 371C (Figure 2e). Chromatix immunoprecipita-
tion assays in TE-1 cells at 321C (active p53) and 371C
(inactive p53) conﬁrmed the presence of both p53 and
NF-kappaB onto COX-2 promoter in cells cultured at
321C, but not at 371C. Overall, results in Figure 2
indicate that NF-kappaB is required for activation of
COX-2 promoter by p53. The two factors cooperate for
transactivation of COX-2 promoter, with effects ranging
from additive to multiplicative, depending on cellular
context.
Effects of mutant p53 on cycloxygenase-2 expression
As the COX-2 promoter does not contain a canonical
p53-binding site, the binding of p53 to the COX-2
promoter may not obey the same structural constraints
than binding to its cognate consensus. As a ﬁrst step to
test this hypothesis, we examined whether mutant p53
may also upregulate Cox-2 expression. HCT116 cells
were transfected with three TP53 mutants, selected as
representative of different classes of mutants
(Figure 3a). A signiﬁcant increase in Cox-2 expression
was observed with R248Q (DNA contact mutant) and
V272M (temperature-sensitive mutant), whereas R175H
(conformation mutant) showed only minimal effects.
Quantitative analysis of COX-2-LUC reporter gene
expression conﬁrmed that R248Q and V272M retained
partial activity, with COX-2-LUC induction levels of
about 50% of that of wild-type p53 (Figure 3b, upper
panel). However, when transfected into p53-deﬁcient,
HCT116-p53/ cells, these mutants did not show any
capacity to increase Cox-2 expression (Figure 3b, lower
panel). Similar results were obtained in another p53-
deﬁcient cell line, Saos-2 (data not shown). Thus, the
effects of mutant p53 on COX-2 promoter appear to
depend on the presence of wild-type p53. Mutant p53
may act by forming complexes with endogenous wild-
type p53. Depending on the type of mutant, these
complexes may retain a degree of COX-2 activating
capacity. In this respect, it is interesting to note that
R175H, the most destructured mutant used here, is the
less effective in inducing Cox-2 expression.
p53 is required for cycloxygenase-2 induction by
daunomycin, a DNA-damaging agent
We next treated HCT116 cells with daunomycin, a
topoisomerase inhibitor that generates strand break
damage and induces p53 stabilization and accumulation.
Daunomycin induced accumulation of endogenous
wild-type p53 and increased Cox-2 protein levels in
HCT116, but not in HCT116-E6 cells (Figure 4a).
Experiments using the COX-2-LUC reporter conﬁrmed
that elimination of p53 by E6 almost totally prevented
COX-2 promoter activation in response to daunomycin
(Figure 4b). Chromatix immunoprecipitation showed
Figure 2 Requirement of (NF-kappaB) for transactivation of COX-2 by p53. (a) Effect of NF-kappaB protein components on COX-2
promoter activation by p53. Cell lines HCT116 (upper panel) and TE-13 (lower panel) were transfected with COX-2-LUC reporter and
increasing amounts of p53, p65 and p50 expression vectors alone or in combination, and RSV-bGAL as transfection standard. LUC activity
was expressed as fold induction relative to the activity observed with reporter alone, normalized to bGAL. (b) A dominant-negative NF-kappaB
inhibitor reduces COX-2 promoter activation by p53. HCT116 and HCT116 MT9 (expressing a dominant-negative IkappaBalpha mutant) were
transfected with COX-2 LUC reporter, increasing amounts of p53 expression vector (pc53-SN3) and RSV-bGAL as transfection standard.
(c) Association of p53 and NF-kappaB with the COX-2 promoter. HCT116 cells were transfected with pC53-SN3 (0.1, 0.3, 1mg). Left, cross-linked
chromatin was immunoprecipitated with anti-p53, anti-NF-kappaB antibodies or control antibody as negative control, and analysed by
polymerase chain reaction (PCR) with primers speciﬁc for COX-2 promoter. MW: molecular weight markers. Input: non-precipitated cross-
linked chromatin. Right, Western blot analysis showing protein levels of Cox-2, p53 and p21 in nontransfected and transfected HCT116, using
Ku80 as loading control. (d) Inhibition of NF-kappaB p65 by siRNA prevents p53-dependent induction of COX-2 expression. Left panel:
HCT116-p53ind cells were transfected with control or with p65 siRNA, followed by tetracycline treatment. WAF-1 and COX-2 mRNA
expression was determined by real-time reverse transcription-PCR (RT–PCR) as in Figure 1c. Right panel: Western blot analysis of p65
expression in HCT116 cells transfected with control, p53 and p65 siRNA, or not transfected (none). Ku80: loading control. (e) The NF-kappaB
inhibitor BAY117082 decreases p53-dependent COX-2 expression. Upper panel: TE-1 cells cultured at 371C were switched to 321C, treated with
BAY117082 (10mM) for 12 h, and COX-2 mRNA expression was determined by real-time RT–PCR as in Figure 1c. Lower panel: cross-linked
chromatin was immunoprecipitated with anti-p53, anti-NF-kappaB antibodies or control antibody as negative control, and analysed by PCR as
in (c).
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that daumomycin induced both p53 and NF-kappaB to
bind to the COX-2 promoter, whereas only p53 binding
was detected on theWAF-1 promoter (Figure 4c). These
results indicate that p53 is required for induction
of Cox-2 by daunomycin through the binding of
NF-kappaB to the COX-2 promoter.
Cycloxygenase-2 expression protects cells against
daunomycin-induced apoptosis
We used a panel of Cox-2 inhibitors to examine the
effects of Cox-2 inhibition on proliferation and survival
after treatment with daunomycin. First, HCT116 cells
were treated with increasing amounts of nimesulid
before treatment with daunomycin. In the absence of
daunomycin, nimesulid had minor effects on prolifera-
tion and survival. However, in the presence of dauno-
mycin, nimesulid strongly reduced proliferation in a
dose-dependent manner (Figure 5a, upper left panel). To
verify that this effect was due to increased apoptosis, we
measured caspase-3 activity in HCT116 treated with
nimesulid or with celecoxib and rofecoxib, two inhibi-
tors of the coxib family. Results showed an increase of
caspase-3 activity with all three Cox-2 inhibitors in cells
treated with daunomycin, but not in untreated cells
(Figure 5a, upper right panel). Treatment with nimesulid
also induced a dose-dependent increase in Poly (ADP-
ribose) polymerase (PARP) cleavage product, an
Figure 3 Effect of mutant p53 on cyclooxygenase-2 (Cox-2)
expression. (a) Induction of Cox-2 expression by mutant p53.
HCT116 cells were co-transfected with increasing amounts of wild-
type (WT) or mutant p53 expression vectors. Top, COX-2 mRNA
was quantitated by real-time PCR using GAPDH as internal
control. Bottom, cell extracts were analysed by Western blot with
anti-Cox-2 antibody using b-actin antibody as loading control.
(b) Wild-type p53-dependent effect of mutant p53 on COX-2
promoter activation. HCT116 (upper panel) or HCT116-p53/
cells were co-transfected with COX-2-LUC reporter, control (Ctrl)
or increasing amounts of WT or mutant p53 expression vectors
(0.1, 0.3, 1mg), and RSV-bGAL as internal transfection control.
LUC activity was expressed as fold induction normalized to bGal.
Figure 4 p53-dependent induction of cyclooxygenase-2 (Cox-2) in
response to daunomycin. (a) p53-dependent increase in Cox-2
protein after treatment with daunomycin. HCT116 and HCT116
E6 cells were treated with daunomycin (2mM, for indicated times).
Cyclooxygenase-2 and p53 proteins were detected by Western blot
using b-actin as loading control. (b) p53-dependent COX-2
promoter activation in response to daunomycin. HCT116 and
HCT116 E6 cells were co-transfected with COX-2-LUC reporter
and RSV-bGAL as transfection control. Six hours after transfec-
tion, cells were exposed to daunomycin (24 h). LUC activity was
expressed as fold induction normalized to bGAL. (c) Recruitment
of p53 and NF-kappaB on COX-2 promoter in response to
daunomycin. Cross-linked chromatin from HCT116 cells exposed
or not exposed to daunomycin (1mM, 24 h) was immunoprecipi-
tated with antibodies to p53, NF-kappaB or control antibody as
negative control, and analysed by polymerase chain reaction with
primers for WAF-1 and COX-2 promoter sequences. Input: non-
precipitated cross-linked chromatin.
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intracellular marker of caspase-3 activation (Figure 5a,
lower panel). Next, we assessed the effects of the two
coxibs on the proliferation of TE-1 at 37 and at 321C
(Figure 5b). At 371C, only rofecoxib had a signiﬁcant
effect on proliferation, with a reduction of 50% in non-
treated and 70% in cells treated by daunomycin. The
effect of celecoxib was less marked and barely reached
statistical signiﬁcance in cells treated with daunomycin.
At 321C, however, both coxibs induced a clear decrease
in cell number owing to massive apoptosis in dauno-
mycin-treated cells. Morphological examination of cells
treated by coxibs and daunomycin conﬁrmed the presence
of many cells exhibiting fragmented nucleus as well as
other typical features of apoptosis (data not shown).
Cycloxygenase-2 expression in relation with TP53
mutation in esophageal cancers
Cycloxygenase-2 expression levels were analysed by
immunohistochemistry in two forms of esophageal
cancers with known TP53 mutation status, namely
SCC (80 cases) and ADC (61 cases). When available,
adjacent, non-cancer mucosa was also examined. A total
of 67 mutations were detected (38/80 in SCC, 48%; 29/
61 in ADC, 48%; see list of mutations in supplementary
data). No expression of Cox-2 was detected in squamous
epithelium adjacent to SCC (Figure 6a, panel 1). High
Cox-2 expression (high Cox-2 cases, deﬁned as intensity
score 2 or 3 in at least 20% of cancer cells) was rare in
low- or high-grade dysplasia (Figure 6a, panel 2) and
was observed in 11% of SCC (9/80) (Figure 6a, panel 3)
In contrast, intestinal (Barrett’s) metaplasia, the precursor
Figure 5 Cyclooxygenase-2 (Cox-2) expression protects cells
against daunomycin-induced apoptosis. (a) Increased daunomy-
cin-induced apoptosis in HCT116 in the presence of Cox-2
inhibitors. Left, HCT116 cells were treated with the indicated
amount of nimesulid before exposure to daunomycin (2mM, 24 h).
Survival, assessed by WST-1 colorimetric assay, was expressed as
percentage of the average value observed with untreated cells.
Right, HCT116 cells were pre-treated with nimesulid (50mM),
celecoxib (10mM) or rofecoxib (2mM) before being exposed or not
exposed (Ctrl) to daunomycin treatment (2mM, 24 h). Cell extracts
were incubated with a ﬂuorogenic caspase-3 substrate, and relative
caspase activation was expressed by normalizing ﬂuorescence to the
level measured in untreated cells. Bottom: Detection of PARP
cleavage product in HCT116 treated with nimesulid before
exposure to daunomycin (2 mM, 24 h). Cell lysates were analysed
by Western blot with anti-cleaved PARP antibody. (b) Enhanced
proapoptotic effects of Cox-2 inhibitors in TE-1 cells cultured at
321C. TE-1 cells were grown at 371C or 321C, treated with
celecoxib (10 mM) or rofecoxib (2mM) before exposure to dauno-
mycin (1 mM, 24 h). Results were expressed by scoring the
percentage of increase (positive values) or decrease (negative
values) in global cell mass as measured using the sulforhodamine
B assay, with 0 representing no change in global cell mass over the
duration of treatment (30 h), positive values representing net cell
growth, and negative values indicating a net decrease in cell mass
owing to massive cell death.
Figure 6 Expression of cyclooxygenase-2 (Cox-2) in esophageal
cancers. (a) Cyclooxygenase-2 immunostaining in representative
sections of normal squamous mucosa (1), squamous dysplasia (2),
in situ squamous cell carcinoma (SCC) (3), Barrett’s mucosa (4, 5)
and adenocarcinoma (ADC) (6). Bars: 10mM. Note the absence of
staining in normal squamous mucosa (1) and patchy staining in
Barrett’s mucosa (5). (b) Correlation between Cox-2 immunopo-
sitivity in cancer and TP53 mutation status. Histograms show, for
SCC and ADC, the proportion of tumors with or without TP53
mutation that express Cox-2 in over 20% of cancer cells. p: Fisher’s
exact test for Cox-2 expression in ADC, mutant vs wild-type TP53.
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lesion for ADC, frequently displayed patches of highly
positive Cox-2 cells in intestinal (Figure 6a, panels 4 and
5), and 44% of ADC (27/61) expressed high levels of
Cox-2, detectable in over 50% of cancer cells in 16/27
cases (Figure 6a, panel 6). Quantitative reverse tran-
scription–polymerase chain reaction (RT–PCR) was
performed in tumor and adjacent non-involved tissue
in six high Cox-2 cases. The average increase in COX-2
mRNA in tumor tissue was 26.7-fold (range 5–100-fold)
(data not shown). In ADC, but not in SCC, there was a
signiﬁcant correlation between high Cox-2 and wild-type
TP53 status. Among cases with wild-type TP53, 72%
expressed high Cox-2, compared to 14% in cases with
mutant TP53 (Po0.01, Fisher’s exact test) (Figure 6b).
Thus, a correlation between TP53 status and COX-2
expression was found in ADC, but not in SCC,
suggesting that the participation of p53 in deregulation
of COX-2 expression in cancer is different according to
tumor histology and natural history.
Discussion
p53 regulates cycloxygenase-2 expression through nuclear
factor-kappaB
The results presented here support the notion that p53 is
a physiological regulator of COX-2 expression in
response to the anticancer drug daunomycin, used here
as a prototypic DNA-damaging agent. These results
also indicate that p53 regulates COX-2 promoter
through an indirect mechanism involving the binding
of NF-kappaB to the COX-2 promoter. This interpreta-
tion is supported by the following observations: ﬁrst,
p50 and/or p65 of NF-KappaB cooperates with p53 for
activation of a COX-2 reporter gene, with additive to
synergistic effects, depending upon cell line; second,
inhibition of NF-kappaB by a dominant-negative I-
kappaB-a mutant signiﬁcantly reduces activation of
COX-2 by p53; third, after transfection of p53, both p53
and NF-kappaB bind to COX-2 promoter, despite the
absence of a canonical p53-binding site; fourth, inhibi-
tion of NF-kappaB using a speciﬁc siRNA prevented
the expression of COX-2, but not WAF-1 RNA after
p53 induction; ﬁfth, a chemical inhibitor of NF-kappaB,
BAY117082, decreases p53-dependent induction of
COX-2 expression in a cell line expressing a tempera-
ture-sensitive p53 mutant. These results are compatible
with those of Han et al. (2002) showing that p53
upregulates Cox-2 expression by an indirect mechanism
(Han et al., 2004). However, how p53 and NF-kappaB
interact at the molecular level remains to be determined.
Mechanisms of p53–nuclear factor-kappaB cooperation
Previous studies have shown that p53 and NF-kappaB
can cooperate in the regulation of gene expression,
however, with conﬂicting results. Webster and Perkins
(1999) observed that both p53 and NF-kappaB inhibited
each other’s ability to stimulate gene expression and that
this process was controlled by the relative levels of each
factor (Webster and Perkins, 1999). In contrast, Ryan
et al. (2000) reported that induction of p53 caused
activation of NF-kappaB and that this phenomenon
correlated with the ability of p53 to induce apoptosis
(Ryan et al., 2000). We previously showed an additive
effect between NF-kappaB subunits and p53 for the
transcriptional activation of TP53 (Benoit et al., 2000).
Bohuslav et al. (2004) described that p53 expression
stimulated the S6 ribosomal serine/threonine kinase
(RSK1), which in turn phosphorylated and activated the
p65/RelA subunit of NF-kappaB (Bohuslav et al.,
2004). Recently, Corcoran et al. (2005) reported that
p53 upregulated Cox-2 expression, which in turn
physically interacts with p53 and inhibits p53-dependent
transcription (Corcoran et al., 2005). A mechanism for
transcriptional inactivation of p53 by products of Cox-2
activity has been proposed by Swamy et al. (2003), who
observed that electrophilic PGs caused wild-type p53
accumulation in the cytosol and inhibition of p53-
dependent apoptosis (Swamy et al., 2003). In HTLV-I
Tax-expressing cells, Jeong et al. (2005) detected an
interaction between p53 and p65/RelA inhibiting p53
transcriptional activity in the absence of NF-kappaB
transcriptional activity. Using ChIP assays, they showed
that in the presence of Tax, both p53 and NF-kappaB
colocalized within the promoter of the p53-responsive
gene MDM2 and repressed its expression. Tax was
unable to inhibit p53 in p65/ mice, indicating that
this effect was NF-kappaB dependent. On the other
hand, this effect was not seen in the absence of Tax,
when both NF-kappaB and p53 were induced (Jeong
et al., 2005). In the present study, we also describe that
p53 and NF-KappaB can colocalize within a promoter
and cooperate in the control of its expression. Thus, our
results show an intriguing symmetry with those of Jeong
et al. (2005). These observations suggest that there may
be different modes of cooperation between NF-kappaB
and p53, in which each factor can recruit the other to
promoters that contain a response element for only one
of them, resulting in either activation or inhibition of
transcription, depending on the promoter and the
cellular context. The nature of effects (from repression
to activation with additive or multiplicative effects) may
depend on how factors synergize or compete in
recruiting co-activators such as CBP/p300, in modifying
local chromatin complex and in modulating the
assembly of transcription initiation complexes. Given
the wide and overlapping range of biological activities of
p53 and NF-kappaB, cooperation between the two
factors may represent a powerful mechanism in the
regulation of the ﬁne balance between pro- and anti-
apoptotic mechanisms controlled by either factor. This
may be of particular relevance in response to DNA
damage during chronic inﬂammation, in conditions
where both factors are activated.
Role of p53 in COX-2 activation in response to DNA
damage
Many stress stimuli activate both p53 and NF-kappaB,
including oxidizing agents such as peroxide and many
pleiotropic DNA-damaging stresses such as ionizing or
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UV-irradiation (Devary et al., 1993; Meyer et al., 1993;
Li and Karin, 1998), making it difﬁcult to identify the
contribution of speciﬁc pathways to COX-2 activation.
The novelty of the data presented here resides in the
demonstration that NF-kappaB is required for COX-2
activation by p53 in response to DNA damage by
daunomycin, a prototypic DNA-damaging agent pri-
marily activating the p53 pathway. With agents having a
wider range of cellular effects, such as hydrogen
peroxide, increase in COX-2 expression was observed
in p53-competent as well as in deﬁcient cells (data not
shown), reﬂecting the capacity of this agent to activate
NF-kappaB through DNA damage-independent path-
ways (Meyer et al., 1993). We suggest that p53 may
provide a plug-in connecting NF-kappaB with DNA
damage signaling pathways. Thus, p53 may not be
required for activation of Cox-2 expression in response
to a number of physiological stimuli. Further studies
comparing DNA-damaging and non-damaging signals
are required to identify signals that induce p53 to
cooperate with NF-kappaB and the nature of post-
translational modiﬁcations involved.
Cycloxygenase-2 inhibitors, TP53 mutations and drug-
induced apoptosis
The proapoptotic effects of Cox-2 inhibitors are well
documented (Sawaoka et al., 1998; Jiang et al., 2002). In
non-small-cell lung cancer cell lines, genetic or pharma-
cological inhibition of Cox-2 enhances proteosomal
degradation of the inhibitor of apoptosis survivin
(Beltrami et al., 2004; Krysan et al., 2004a, b). In turn,
depletion of survivin causes arrest of DNA synthesis
owing to activation of p53 and p21Waf1 (Beltrami et al.,
2004; Yang et al., 2004). Thus, in tumor cells with wild-
type p53, inhibition of Cox-2 may result in increased
p53-dependent growth suppression. In agreement with
this notion, we found that Cox-2 inhibitors sensitized
cultured cells to apoptosis induced by daunomycin, and
that this effect was more marked in cells that retained
active p53. In particular, the proapoptotic effects of
coxibs were greater in TE-1 cells at 321C (expressing
predominantly p53 in an active, wild-type-like form)
than at 371C (expressing predominantly mutant, in-
active p53). These observations imply that Cox-2
expression acts as a survival mechanism in cells exposed
to forms of damage that activates p53 and may therefore
result into apoptosis. In this respect, Cox-2 may have an
important contribution in keeping cells alive after DNA
damage, tilting the balance towards p53-mediated arrest
rather than apoptosis. We believe that chronic inﬂam-
mation may represent a physio-pathological context in
which p53 and NF-kappaB cooperate to activate Cox-2.
Inﬂammatory cells are subjected to a number of signals
that activate both factors. In particular, during the
inﬂammatory process, intracellular reactive oxygen and
nitrogen species are produced, damaging DNA and
inducing p53 activation. In such a context, the
cooperation between p53 and NF-kappaB may be a
critical factor in determining the fate of cells under
inﬂammatory stress.
Cycloxygenase-2 expression in relation with TP53 status
in esophageal cancer
On the basis of the results above, it is predicted that
overexpression of Cox-2 in inﬂammatory pre-cancer and
cancer tissues may correlate with wild-type TP53 status.
Despite numerous studies on Cox-2 expression in
relation with p53 immunostaining in cancer cells, a
correlation between the expression of the two markers
has not been demonstrated. Our study in esophageal
cancers shed a new light on this question. A correlation
between Cox-2 expression and TP53 mutation status
was observed in ADC, but not in SCC. In SCC, Cox-2
expression was not detected in normal mucosa adjacent
to cancer but was observed in dysplasias (low- and high-
grade) and in a small proportion (11%) of invasive SCC,
without correlation with either TP53 gene status or p53
protein expression. These results are consistent with
observations by others, although most series have
reported high levels of Cox-2 expression in a larger
proportion of SCC (Shamma et al., 2000; Kuo et al.,
2003; Yu et al., 2003). Detection of high levels of Cox-2
in dysplasias suggests that overexpression is a marker
for intense cell proliferation in early disease (Kuo et al.,
2003). In contrast, in ADC, Cox-2 expression was
frequent in cells of Barrett’s esophagus (BE), the
precursor lesion, even in the absence of dysplasia,
consistent with the inﬂammatory nature of this lesion.
This high Cox-2 pattern was retained in 44% of cancers,
irrespective of tumor grade and stage. Tumors with high
Cox-2 were signiﬁcantly more likely to harbor wild-type
TP53 than tumors with low Cox-2. Barrett’s esophagus
develops as a consequence of exposure of the lower
esophagus to gastric reﬂux stress. Exposure to bile salt
and acid upregulates Cox-2 in explants of Barrett’s
mucosa (Shirvani et al., 2000; Kaur and Triadaﬁlopou-
los, 2002). Inhibition of Cox-2 by rofecoxib inhibits cell
proliferation in BE (Kaur et al., 2002). There is also
evidence that NF-kappaB activity is signiﬁcantly in-
creased in BE and is an important contributor to
neoplastic progression (Konturek et al., 2004). Thus,
cooperation between p53 and NF-kappaB increasing
Cox-2 expression may represent an adaptative response
of cells to stress by reﬂux that promotes the proliferation
and survival of cells with high potential to progress
toward ADC.
In conclusion, we describe here a novel mechanism of
transcriptional regulation of COX-2 by p53, in which
p53 cooperates with NF-kappaB to activate transcrip-
tion through the kappaB response element. This
mechanism induces anti-apoptotic effects that can be
neutralized using therapeutic Cox-2 inhibitors. The
cooperation between p53 and NF-kappaB may play a
physiological role to neutralize apoptosis in response to
DNA damage generated during inﬂammation. In pre-
cursor cancer lesions such as BE, p53-dependent
expression of COX-2 may provide a mechanism for
escape from apoptosis and progression toward neoplasia
in a highly inﬂammatory context. A recent study has
shown that PGE2 stimulates colon cancer growth by
activating a cascade that involves the inactivation and
release of glycogen synthase kinase 3b from its complex
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with axin, thereby activating b-catenin signaling path-
way (Castellone et al., 2005). Detailed understanding of
these mechanisms will allow to determine in which types
of cancer COX-2 inhibitors may enhance clinical
responses to therapeutic drugs.
Materials and methods
Cell lines, transfections and reporter assays
Cell lines TE-1, TE-6 and TE-13 (esophageal SCC) were
cultured in RPMI supplemented with 10% fetal calf serum
(PAA), penicillin/streptomycin/glutamine (Gibco BRL,
Gaithersburg, MD, USA), at 371C under 10% CO2. TP53
mutation status and temperature sensitivity of TE-1 has been
reported elsewhere (Barnas et al., 1997; North et al., 2002).
HCT116 (colon carcinoma (ATCC CCL247) and HCT116/
p53/ (kindly given by B Vogelstein) were grown in
McCoy’s 5A modiﬁed medium supplemented with 1% L-
glutamine, 1% antibiotics and 10% fetal bovine serum (Life
Technologies, Cergy Pontoise, France). HCT116 MT9 and
HCT116 E6 were grown in the same medium supplemented
with G418 (geneticin, 0.5mg/ml, Roche, Manneheim, Ger-
many) (Bentires-Alj et al., 1999a). The following drugs were
added in culture medium of exponentially growing cells: BAY
11-7082 (Sigma-Aldrich, St Louis, MO, USA), daunomycin
(Cerubidine, Rhone-Poulenc Rorer) and Cox-2 inhibitors
nimesulid, celecoxib and rofecoxib (provided by Dr X de
Leval, Laboratory of Pharmaceutical Chemistry, University of
Lie`ge, Belgium). Transfections were performed with FuGENE
(1.5 ml/mg DNA) (Roche, Mannheim, Germany). RNA inter-
ference to inhibit NF-kappaB p65 was performed using 10 nM
of siRNA from the kit OR-KIT2-SIRA (Eurogentec, Seraing,
Belgique) according to the manufacturer’s instructions. The
sequence OR-0030-neg, from the same supplier, was used as
negative control. Transfections were performed using HiPer-
Fect (QiaGen, Venlo, The Netherlands, catalogue number
301705). For Luciferase assays, HCT116 plated at a density of
5 105 cells per 35-mm culture dish was transfected with a
reporter gene (0.5 mg) containing 50-ﬂanking sequences (891
to þ 9) of human COX-2 gene constructed into the promotor-
less luciferase expression vector pGL3 (COX-2-Luc, gift from
Professor KK Wu, Houston, TX, USA) (Gilroy et al., 2001),
RSV-bGAL plasmid (0.2 mg) and indicated amounts of
expression vectors. Total amount of DNA was kept constant
by addition of vector-only pcDNA3 plasmid. After 24 h,
luciferase activity was determined using Luciferase Reporter
Gene Assay kit and bGalactosidase activity was assessed with
Chemoluminescent bGal Reporter Gene Assay Kit (Roche).
Luciferase activities were normalized with bGal and expressed
as fold induction relative to activity with reporter plasmid
alone.
Western blotting
Cells were lysed in RIPA-like buffer (250mM NaCl, 50mM
Tris-HCl pH 7.4, 0.1% sodium dodecyl sulfate (SDS), 2mM
Dithiothreitol, 0.5% NP40) containing protease inhibitors
(completet, Roche). After clearing by centrifugation, an equal
amount of proteins were resolved onto 10% SDS–polyacryla-
mide gel electrophoresis (PAGE), transferred to nitrocellulose,
probed with appropriate antibodies and revealed with en-
hanced chemiluminescence (ECL, Amersham, UK). The
following antibodies were used: p53 (DO7, Dako, Glostrup,
Denmark, 1/1000), Cox-2 (C20, Santa Cruz, CA, USA, 1/
1000), p21Waf1 (C19, Santa Cruz, 1/1000), cleaved PARP (BD
Pharmingen, San Diego, CA, USA, 1/1000), anti-b-actin (C4,
Santa Cruz, 1/10 000).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed as
described by Strano et al. (2002). After cross-linking with
formaldehyde (1% ﬁnal concentration) for 10min and
neutralization in 125mM glycine pH 2.5, cells were lysed for
15min at 41C in SDS-lysis buffer (1% SDS, 10mM ethylene
diamin tetraacetic acid (EDTA), 50mM Tris-HCl) containing
protease inhibitors. Lysates were sonicated to generate 200–
1000 bp DNA fragments, cleared by centrifugation and diluted
10-fold with immunoprecipitation buffer (16.7mM Tris-HCl,
pH 8.1, 167mM NaCl, 1.2mM EDTA, 0.01% SDS, 1.1%
Triton X-100). After preclearing with salmon sperm DNA/
protein G agarose beads (Upstate, Charlottesville, VA, UK),
lysates were incubated overnight with anti-p53 (CM-1,
Novocastra, Newcastle, UK), anti-NF-kappaB p65 (sc-109,
Santa Cruz) polyclonal antibodies or an irrelevant antibody
(labeled as Control, Ctrl, in relevant ﬁgures) as negative
control. Immunoprecipitated complexes were collected with
salmon sperm DNA/protein G agarose beads, washed, and
eluted with 1% SDS, 0.1M NaHCO3. Cross-linking of
protein–DNA complexes was reversed at 651C for 4 h, DNA
was digested with 10mg/ml of proteinase K for 1 h at 451C,
and recovered by phenol/chloroform extraction and ethanol
precipitation. Detection of promoters was performed with the
following primers: COX-2: F 50-CTGTTGAAAGCAACTTA
GCT-30, R 50-AGACTGAAAACCAAGCCCAT-30, p21WAF1:
F 50-CATTGTTCCCQGCACTTCCTCTC-30, R 50-AGAAAG
CCAATCAGAGCCACAG-30.
Cell proliferation, prostagladin E2 activity and caspase assays
Cells were plated in 96-well plates (5000 cells/well) and
incubated with daunomycin and/or Cox-2 inhibitors for 24 h.
Cell viability was assessed by WST-1 colorimetric test (Roche)
and cell numbers were determined using the sulforhodamine B
(SRB) colorimetric assay (Skehan et al., 1990). For PGE2
assay, TE-1 cells were plated in six-well plates at a density of
106 cells/well, grown for 24 h at indicated temperature, and
PGE2 in culture medium was measured by enzyme immu-
noassay (R&D systems, Abingdon, UK). Levels of PGE2 were
normalized according to the number of cells at the time of the
medium collection. The results were expressed in nanograms of
PGE2 per 10
5 cells. Caspase-3 activation test was performed
using the caspase-3 ﬂuorometric assay kit (Alexis Biochem-
icals, Lausen, Switzerland). In brief, HCT116 cells pre-treated
or not pre-treated with Cox-2 inhibitors were exposed to
daunomycin. Cell lysates were incubated with a caspase-3
ﬂuorogenic substrate and the ﬂuorescence of generated cleaved
product was measured with a spectroﬂuorometer (460 nm).
Semiquantitative and real-time reverse transcription-polymerase
chain reaction
Total RNA isolated from cell lines or frozen tissues using
Trizol (Gibco-BRL, Gaithersburg, MD, USA) was reverse
transcribed with SuperScriptt Reverse Transcriptase (Invitro-
gen, Cergy Pontoise, France). COX-2 cDNA (F 50-GTTT
GCATTCTTTGCCCAGC-30 and R 50-CAGGCACCAGAC
CAAAGACC-30) was co-ampliﬁed with b-actin (F 50-GACAC
CACTGGAGGGTGACT-30 and R 50-CCACATGGTCTTC
CTCTGCT-30) for semiquantitative analysis. A PCR ampliﬁ-
cation cycle included denaturation at 941C for 30 s, annealing
at 591C for 30 s and extension at 721C for 5min. Real-time
PCR was performed with ABI Prism 7900 HT Sequence
Detection System (Applied Biosystems, Courtaboeuf, France).
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Relative quantiﬁcation was performed in a multiplex reaction
using b-actin as endogenous control. The primers and
ﬂuorogenic probes for PCR reactions were the following:
COX-2: F 50-GCCCTTCCTCCTGTGCC-30, R 50-AATCAG
GAAGCTGCTTTTTAC-30/50 FAM-ATGATTGCCCGACT
CCCTTGGGGTGT-BHQ1 30 and b-actin: F 50-CTGGCA
CCCAGCACAATG-30, R 50-GCCGATCCACACGGAGTA
CT-30/50 TET-TCAAGATCATTGCTCCTCCTGAGCGC-
BHQ1 30. Each sample was analysed in quadruplicate. Relative
quantiﬁcation was performed using the comparative threshold
cycle (CT) method as described in the User Bulletin, ABI
PRISM 7900 HT Sequence Detection System.
Tumor tissues, cyclooxygenase-2 immunohistochemistry and
TP53 mutations
A consecutive series of 141 patients with esophageal cancer
were recruited at Edouard Herriot Hospital, Lyon (France)
between 1995 and 2002, including 80 SCC and 61 ADC with
pathological evidence of Barrett’s metaplasia (Siewert and
Stein, 1998). All tumors were locally invasive, T3 or T4
carcinoma in patients who did not receive chemo- or radio-
therapy before resection or biopsy. Tissues were formalin ﬁxed
and parafﬁn embedded using standard methods. For immu-
nohistochemistry, rehydrated tissue sections were exposed
overnight at 41C to the anti-Cox-2 polyclonal antibody C-20
(1/1000, Santa Cruz) and ﬁxed antibodies were detected using
biotinylated anti-rabbit IgG (1/200, Vectasin Elite-ADC kit,
Vector Laboratories Inc., Burlingame, CA, USA) followed by
streptavidin–peroxidase and diaminobenzidine-based detec-
tion (Vector Laboratories). Tumors were scored by evaluating
the percentage of tumor cells that stained for Cox-2 and were
considered as positive when containing over 20% of stained
tumor cells. TP53 mutation detection (exons 4–9) was
performed by temporal temperature gradient electrophoresis
(TTGE) using the DCode system (BioRad, Marnes La
Coquette, France) using primers and conditions described
elsewhere (Sepehr et al., 2001) and DNA segments that
generated abnormal TTGE proﬁles were further analysed by
sequencing on ABI Prism 3100 automated sequencer. All
mutations were conﬁrmed by a second, independent sequence
analysis using the same primers.
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